Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - voriconazol - filmtablette - teil 1 - filmtablette; voriconazol (26980) 50 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

heumann pharma gmbh & co. generica kg (8120809) - voriconazol - filmtablette - teil 1 - filmtablette; voriconazol (26980) 200 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

heumann pharma gmbh & co. generica kg (8120809) - voriconazol - filmtablette - teil 1 - filmtablette; voriconazol (26980) 50 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dyckerhoff pharma gmbh & co.kg - ribonucleinsäure-natriumsalz - injektionslösung - ribonucleinsäure-natriumsalz 6.3mg

Europäische Union - Deutsch - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - nasse makula-degeneration - ophthalmika - beovu ist indiziert bei erwachsenen für die behandlung von neovascular (wet) age-related macular degeneration (amd).

Europäische Union - Deutsch - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmika - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europäische Union - Deutsch - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmika - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europäische Union - Deutsch - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmika - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europäische Union - Deutsch - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmika - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

baxalta innovations gmbh - immunglobulin - immunglobuline, normal